Agenus Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-14$4.68 RISE2026-02-05$2.77 PEAK2026-04-15$4.83 91d | -40.8% 22d | Missed | Missed | — | — | +74.4% 69d | Missed |
DROP2025-07-11$7.06 RISE2025-11-05$3.69 PEAK2026-01-14$4.68 187d | -47.7% 117d | Missed | Missed | — | — | +26.8% 70d | Missed |
DROP2025-07-11$7.06 RISE2025-09-30$3.85 PEAK2025-11-28$4.56 140d | -45.5% 81d | Missed | Missed | — | — | +18.4% 59d | Missed |
DROP2025-02-05$3.90 RISE2025-03-31$1.51 PEAK2025-06-06$5.95 121d | -61.3% 54d | Missed | Missed | — | — | +294.0% 67d | Missed |
DROP2024-09-13$6.26 RISE2024-12-30$2.69 PEAK2025-02-05$3.90 145d | -57.0% 108d | Missed | Missed | — | — | +45.0% 37d | Missed |
DROP2024-07-17$17.73 RISE2024-11-19$2.57 PEAK2025-02-05$3.90 203d | -85.5% 125d | Missed | Missed | — | — | +51.8% 78d | Missed |
DROP2024-07-17$17.73 RISE2024-08-14$4.58 PEAK2024-09-13$6.26 58d | -74.2% 28d | Missed | Missed | — | — | +36.7% 30d | Missed |
DROP2024-02-14$18.60 RISE2024-04-18$4.97 PEAK2024-07-16$17.70 153d | -73.3% 64d | Missed | Missed | — | — | +256.1% 89d | Missed |
DROP2023-09-15$26.20 RISE2024-01-18$11.20 PEAK2024-02-14$18.60 152d | -57.3% 125d | Missed | Missed | — | — | +66.1% 27d | Missed |
DROP2023-07-12$37.60 RISE2023-11-13$12.60 PEAK2023-12-04$16.60 145d | -66.5% 124d | Missed | Missed | — | — | +31.7% 21d | Missed |
DROP2023-06-08$40.80 RISE2023-08-08$25.00 PEAK2023-08-22$30.20 75d | -38.7% 61d | Missed | Missed | — | — | +20.8% 14d | Missed |
DROP2023-01-13$57.90 RISE2023-05-24$28.00 PEAK2023-06-08$40.80 146d | -51.6% 131d | Missed | Missed | — | — | +45.7% 15d | Missed |
DROP2023-01-13$57.90 RISE2023-05-19$28.00 PEAK2023-06-08$40.80 146d | -51.6% 126d | Missed | Missed | — | — | +45.7% 20d | Missed |
DROP2023-01-13$57.90 RISE2023-05-16$28.00 PEAK2023-06-08$40.80 146d | -51.6% 123d | Missed | Missed | — | — | +45.7% 23d | Missed |
DROP2023-01-13$57.90 RISE2023-05-11$28.00 PEAK2023-06-08$40.80 146d | -51.6% 118d | Missed | Missed | — | — | +45.7% 28d | Missed |
1–15 / 27 1 / 2 | |||||||
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
BP (BP) has ousted Chairman Albert Manifold with immediate effect over what the company called âserious concernsâ related to governance standards, oversight and conduct.
LEXINGTON, Mass., May 21, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus’ multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with advanced cutaneous melanoma refractory or resistant to prior anti-PD-(L)1 therapy, including patients previously treated with anti-CTLA-4 therapy. The full dataset will b
LEXINGTON, Mass., May 21, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetik’s artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology images in patients treated with botensilimab (BOT) plus balstilimab (BAL), Agenus’ investigational next-generation multifunctional, Fc-enhanced anti-CTLA-4 and anti-PD-
First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease featuresIn the overall BOT+BAL treated population, median
Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survivalIn a retrospective
LEXINGTON, Mass., May 15, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in patients with treatment-refractory hepatocellular carcinoma (HCC) who had progressed following prior immunotherapy. The manuscript, titled "A phase 1b study of botensilimab and balstilimab in treatment-refractory hepat
Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapyMedian overall survival of 12.3 months in a heavily pretreated population with poor prognostic
Agenus (AGEN) delivered earnings and revenue surprises of -51.43% and -73.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) delivered earnings and revenue surprises of -51.43% and -73.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
LEXINGTON, Mass. — LEXINGTON, Mass. — Agenus Inc. on Monday reported first-quarter net income of $39.2 million, after reporting a loss in the same period a year earlier. The Lexington,...
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AGEN | -8.85% | +4.79% | +11.46% | +2.04% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.82% | +10.51% | +14.91% | -10.65% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 285.6K | $954.06K | 0.00% | Trimmed-47.4% | 2026-03-31 |
| TwoSigma | quant | 170.9K | $570.88K | 0.00% | Added+45.9% | 2026-03-31 |
| StateStreet | passive | 156.2K | $521.65K | 0.00% | Added+13.7% | 2026-03-31 |
| DEShaw | quant | 33.3K | $111.12K | 0.00% | Trimmed-73.9% | 2026-03-31 |
| FidelityFMR | fundamental | 5.4K | $18.05K | 0.00% | Unchanged | 2026-03-31 |
| TRowePrice | fundamental | 24.5K | $82 | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -0.40 | — | — |
| 2026-05-11 | 1.80 | -0.03 | -101.77% |
| 2026-03-16 | -1.05 | -0.37 | +64.76% |
| 2025-11-10 | 2.20 | -1.16 | -152.92% |
| 2025-08-11 | 1.35 | -1.00 | -173.89% |
| 2025-05-12 | -1.98 | -1.03 | +47.98% |
| 2025-03-17 | -2.54 | -2.04 | +19.75% |
| 2024-11-12 | -2.31 | -3.08 | -33.10% |
| 2024-08-08 | -1.33 | -2.52 | -89.83% |
| 2024-05-07 | -3.22 | -3.04 | +5.47% |
| 2024-03-14 | -1.05 | -2.60 | -147.62% |
| 2023-11-07 | -3.95 | -3.20 | +18.99% |
| 2023-08-08 | -3.96 | -4.00 | -1.01% |
| 2023-05-09 | -4.20 | -4.40 | -4.76% |
| 2023-03-14 | -4.33 | -4.80 | -10.77% |
| 2022-11-08 | -3.60 | -3.80 | -5.56% |